About Affinium
Affinium is a specialty pharmaceutical company developing a novel class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, our lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.
Established in 2000 to commercialize its structure-guided drug development expertise, Affinium has focused since December 2002 on small molecule antibacterials which inhibit the FASII pathway and has built an international patent portfolio of more than 1,700 compounds, targets and assays in this new therapeutic class. Affinium’s first clinical candidate, AFN-1252, has demonstrated excellent tolerability in two phase 1 clinical trials with an oral formulation. Additional oral clinical trials and development of an IV formulation for AFN-1252 are ongoing.
Affinium is headquartered in Austin, Texas, with operations in Toronto, Ontario. Affinium is interested in worldwide out-licensing of AFN-1252 and other active small molecules that exhibit in vitro antibacterial activity against additional relevant pathogenic bacteria.
Duo an num quam fuisset sadipscing, elit animal doc endi enum num ut.